About Lupus Therapeutics

Lupus Therapeutics was established by the Lupus Research Alliance to advance lupus clinical research by finding more effective and safer treatments for people living with lupus. During the past sixty years, only two new drugs have been approved to treat lupus, a complex autoimmune disease that can affect people differently and change over time. We are passionate about changing the course of lupus research and finding individual treatments and hopefully, a cure.

This is a strategic investment that we invite every stakeholder in the lupus community to take part in—patients, researchers and industry.

About Lupus Therapeutics

Lupus Therapeutics was established by the Lupus Research Alliance to advance lupus clinical research by finding more effective and safer treatments for people living with lupus. During the past sixty years, only two new drugs have been approved to treat lupus, a complex autoimmune disease that can affect people differently and change over time. We are passionate about changing the course of lupus research and finding individual treatments and hopefully, a cure.

This is a strategic investment that we invite every stakeholder in the lupus community to take part in—patients, researchers and industry.

About Lupus Therapeutics

Lupus Therapeutics was established to advance lupus clinical research by finding more effective and safer treatments for people living with lupus. During the past sixty years, only one new drug has been approved to treat lupus, a complex autoimmune disease that can affect people differently and change over time. We are passionate about changing the course of lupus research and finding individual treatments and hopefully, a cure.

This is an aspirational investment that we invite every stakeholder in the lupus community to take part in—patients, doctors, researchers and industry.

Executive Leadership

Albert Roy

Al serves as the Executive Director of Lupus Therapeutics and is responsible for the planning, directing, and coordinating the organization’s core business operations and the Alliance’s clinical trial endeavors.

Full bio

Lupus Therapeutics Board of Directors

Joseph Craft, MD (Chair)

Paul B. Beeson Professor of Medicine and Professor of Immunobiology at the Yale School of Medicine, and past chief of the Section of Rheumatology at Yale.

Full bio
Cantey Boyd 

Cantey serves as a Managing Director of Baker Brothers Investments, a fund management company focused on long-term investments in life-sciences companies. Before joining Baker Brothers in 2005, Ms. Boyd worked in investment banking at Deutsche Bank.

Full bio
Jennie DeScherer 

Jennie is an active Board member of the Lupus Research Alliance having helped lead its predecessor organizations – S.L.E. Lupus Foundation (S.L.E.) and the Lupus Research Institute (LRI) – since their early years.

Full bio
Kenneth Farber

Ken serves as the President and CEO of the Lupus Research Alliance. Ken is a graduate of Clark University, with a Juris Doctor from the Fordham University School of Law. He has spent 40 years in the non-profit world, working with and for voluntary health agencies and private foundations.

Full bio
Mark C. Genovese, MD

Dr. Genovese is the SVP for Inflammation Clinical Research at Gilead Sciences. He oversees all clinical research endeavors in the areas of Rheumatology, Pulmonary, GI, Liver, Kidney, and Male Health at Gilead Sciences.

Full bio
Brian Kotzin, MD

Dr. Kotzin has been committed to patient care, research, and teaching during his 25-year academic career. He currently serves as a Senior Vice President at Nektar Therapeutics.

Full bio
Joe Mauriello

Joseph retired in 2006 as Deputy Chairman & COO of KPMG, after 40 years in various leadership positions. He is also a member of the Board of Trustees of the St. Barnabas Medical Center in Livingston, NJ.

Full bio
Kelly McVearry, PhD, MA, Ed.M.

Kelly has two decades of experience leading the design, development, due diligence and commercialization of life science and information technologies.

Full bio
Alexander von Perfall

Alexander joined Royalty Pharma in 2009 as Vice President, Investor Relations & Public Affairs. Earlier, Mr. von Perfall was the Co-Founder and Chief Network Officer of XTF, a start-up exchange-traded fund ratings agency.

Full bio
Daniel J Wallace MD, FACP, MACR 

Dr. Wallace is a board-certified internist and rheumatologist. A Clinical Professor of Medicine at the David Geffen School of Medicine at UCLA, he is the Associate Director of the Rheumatology Fellowship Program at Cedars-Sinai Medical Center where he also serves on the Board of Governors.

Full bio
Kimberly Williams 

Kimberly currently serves as Director of Public Affairs and Alliance Development for Novo Nordisk, Inc., one of this nation’s largest pharmaceutical companies where her responsibilities include support for company priorities around alliance development and advocacy with Specialty patient and physician organizations.

Full bio
William Wolfe

Co-founder and Chairman of First Washington Realty, Inc., a privately held real estate investment advisory firm specializing in ownership of major metropolitan area shopping centers.

Full bio

Our Partners

Discover our solutions

A research innovation accelerator dedicated to improving lupus treatments and advancing research toward a cure, ONLY Lupus Therapeutics has a track record of successfully collaborating with more than a dozen top global pharmaceutical companies working on lupus clinical studies.

Learn more

Discover our solutions

A research innovation accelerator dedicated to improving lupus treatments and advancing research toward a cure, ONLY Lupus Therapeutics has a track record of successfully collaborating with more than a dozen top global pharmaceutical companies working on lupus clinical studies.

Learn more